-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

Benzinga·07/22/2026 10:42:36
语音播报
B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.